Historical Valuation
Arcutis Biotherapeutics Inc (ARQT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8.08 is considered Overvalued compared with the five-year average of -7.48. The fair price of Arcutis Biotherapeutics Inc (ARQT) is between 18.19 to 24.31 according to relative valuation methord. Compared to the current price of 28.22 USD , Arcutis Biotherapeutics Inc is Overvalued By 16.07%.
Relative Value
Fair Zone
18.19-24.31
Current Price：28.22
16.07%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Arcutis Biotherapeutics Inc (ARQT) has a current Price-to-Book (P/B) ratio of 22.07. Compared to its 3-year average P/B ratio of 8.49 , the current P/B ratio is approximately 159.83% higher. Relative to its 5-year average P/B ratio of 6.60, the current P/B ratio is about 234.57% higher. Arcutis Biotherapeutics Inc (ARQT) has a Forward Free Cash Flow (FCF) yield of approximately -0.94%. Compared to its 3-year average FCF yield of -29.97%, the current FCF yield is approximately -96.88% lower. Relative to its 5-year average FCF yield of -24.25% , the current FCF yield is about -96.14% lower.
P/B
Median3y
8.49
Median5y
6.60
FCF Yield
Median3y
-29.97
Median5y
-24.25
Competitors Valuation Multiple
AI Analysis for ARQT
The average P/S ratio for ARQT competitors is 6.37, providing a benchmark for relative valuation. Arcutis Biotherapeutics Inc Corp (ARQT.O) exhibits a P/S ratio of 8.08, which is 26.83% above the industry average. Given its robust revenue growth of 121.69%, this premium appears sustainable.
Performance Decomposition
AI Analysis for ARQT
1Y
3Y
5Y
Market capitalization of ARQT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ARQT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ARQT currently overvalued or undervalued?
Arcutis Biotherapeutics Inc (ARQT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8.08 is considered Overvalued compared with the five-year average of -7.48. The fair price of Arcutis Biotherapeutics Inc (ARQT) is between 18.19 to 24.31 according to relative valuation methord. Compared to the current price of 28.22 USD , Arcutis Biotherapeutics Inc is Overvalued By 16.07% .
What is Arcutis Biotherapeutics Inc (ARQT) fair value?
ARQT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Arcutis Biotherapeutics Inc (ARQT) is between 18.19 to 24.31 according to relative valuation methord.
How does ARQT's valuation metrics compare to the industry average?
The average P/S ratio for ARQT's competitors is 6.37, providing a benchmark for relative valuation. Arcutis Biotherapeutics Inc Corp (ARQT) exhibits a P/S ratio of 8.08, which is 26.83% above the industry average. Given its robust revenue growth of 121.69%, this premium appears sustainable.
What is the current P/B ratio for Arcutis Biotherapeutics Inc (ARQT) as of Jan 10 2026?
As of Jan 10 2026, Arcutis Biotherapeutics Inc (ARQT) has a P/B ratio of 22.07. This indicates that the market values ARQT at 22.07 times its book value.
What is the current FCF Yield for Arcutis Biotherapeutics Inc (ARQT) as of Jan 10 2026?
As of Jan 10 2026, Arcutis Biotherapeutics Inc (ARQT) has a FCF Yield of -0.94%. This means that for every dollar of Arcutis Biotherapeutics Inc’s market capitalization, the company generates -0.94 cents in free cash flow.
What is the current Forward P/E ratio for Arcutis Biotherapeutics Inc (ARQT) as of Jan 10 2026?
As of Jan 10 2026, Arcutis Biotherapeutics Inc (ARQT) has a Forward P/E ratio of 76.52. This means the market is willing to pay $76.52 for every dollar of Arcutis Biotherapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Arcutis Biotherapeutics Inc (ARQT) as of Jan 10 2026?
As of Jan 10 2026, Arcutis Biotherapeutics Inc (ARQT) has a Forward P/S ratio of 8.08. This means the market is valuing ARQT at $8.08 for every dollar of expected revenue over the next 12 months.